Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07303777 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date changed from estimate of Apr 2026 to Apr 23, 2026
    • Site details revised at 33 of 33 sites
    v5
  2. Study sites revised (33)v4
  3. Start date: Feb 2026 to Apr 2026
    • Study sites: 4 to 33
    v3
  4. Primary completion date: Mar 2028 to Jan 2028
    • Study completion date: Jul 2028 to Apr 2028
    • Study title shortened, about 7 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.
Trial Details
NCT Number NCT07303777
Lead Sponsor Atom Therapeutics Co., Ltd
Conditions
(from sponsor)		 Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov